값Q4, 24TTM판매비·일반관리비——연구개발——영업 이익——비영업 수익, 합계——이자비용(자본화한 이자 차감 후)——이자비용을 제외한 비영업 수익——비정상 수입/지출——세전소득——지분법 손익——세금——비지배 지분——세후 기타 수익/비용——중단된 사업 부문 제외 순이익——중단된 사업——순이익——희석보정——우선배당——보통주주에게 귀속되는 희석 순이익——주당 순이익(기본 EPS)——희석 주당 순이익 (희석 EPS)——평균 발행주식수——희석주식수——EBITDA——EBIT——매출원가——기타 매출원가——감가상각 및 무형자산 상각 (현금흐름)——
Cybin Inc. - Common Stock
Helus Pharma, also known formerly as Cybin IRL, is a Canadian pharmaceutical company that was led by CEO Doug Drysdale from 2020-2025, developing psychedelic drugs as medicines.
The company's drug candidates include psilocybin, HLP002, HLP003, HLP004, HLP005, and HLP006. Another drug that the company has developed is CYB210010.
As of January 2025, HLP003 is in phase 3 clinical trials. The drug is one of the only other psychedelics besides Compass Pathways's COMP360 to have reached this late stage of clinical development.
In 2020, Helus Pharma acquired psychedelic pharmaceutical company Adelia Therapeutics. In late 2023, it acquired Small Pharma, the developer of SPL026 and SPL028. Helus Pharma was originally known as Cybin but changed its name in December 2025.